1. Market Research
  2. > Healthcare
  3. > Medical Device
  4. > Cardiovascular Devices Market Trends
  5. > MediPoint: Coronary Stents - US Analysis and Market Forecasts

MediPoint: Coronary Stents - US Analysis and Market Forecasts

Summary

The global coronary stents market is a dynamic, double-digit market that is saturated with numerous players developing innovative technologies. Rapid advances in the field of interventional cardiology along with the development of minimally invasive techniques have greatly expanded the potential of therapeutic applications. Coronary stents including bare metal, drug-eluting, covered and bioabsorbable stents can be used to treat coronary artery disease, and optimize outcomes.

Each year, millions of individuals are affected by CAD worldwide. Given the high burden of the disease, it is important to develop innovative technologies that can improve outcomes and disease management. Stenting for coronary applications has been widely adopted in clinical practice worldwide, and can be used in a wide range of indications. Among the different types of stents available, DES dominate the market. As BAS enter the US, Japanese, and Chinese markets, and their designs are improved, the next generation of DES with biodegradable polymer/polymer-free coatings are adopted, long-term clinical data become available, and appropriate reimbursement rates are established, GlobalData believes that the coronary stent market will increase in the future. By 2020, the coronary stents market for BMS and DES is estimated to be over $5.61 billion.

Scope

- An overview of Coronary Stents, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized the US Coronary Stents market revenue and future forecasts from 2011 to 2013, forecast for 7 years to 2020.
- Investigation of current and future market competition for Coronary Stents.
- Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
- Competitor assessment including device approval analysis and device sales forecasts.
- Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
- Analysis of unmet needs within the market and opportunities for future players.
- Technology trends evaluation to assess strength of pipeline.
- An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
- Company profiles including business description, financial overview and SWOT analysis.
- Coverage of key market players.
- Strategic assessment of the Coronary Stents sector through market impact analysis, future market scenario and company analysis.
- Direct quotes from Key Opinion Leaders (KOL) as well as doctors

Reasons to buy

- Understand the trends shaping and driving the US Coronary Stents market.
- Realize device preferences of physicians who have performed the tests already.
- Access market sizing, forecasts and quantified growth opportunities in the US Coronary Stents market through 2018.
- Quantify candidate patient populations to better design product pricing & launch plans.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
- Perform benchmarking analysis of growth opportunities against currently marketed products.
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Take a comprehensive look at the market’s device pipeline and identify promising, paradigm-shifting products.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
- What’s the next big thing in the US Coronary Stents market landscape? Identify, understand and capitalize.

Table Of Contents

MediPoint: Coronary Stents - US Analysis and Market Forecasts
1 Table of Contents

2 Introduction 27
2.1 Catalyst 28
2.2 Related Reports 29
3 Industry Overview 30
3.1 Disease Overview 30
3.2 Clinical Outcomes 31
3.2.1 Treatment Guidelines 31
3.2.2 Treatment Modalities 32
3.3 Procedure Trends 46
3.3.1 United States 47
3.4 Market Access 49
3.4.1 Regulatory Process 50
3.4.2 Physician Decision-Making Process 50
3.4.3 Role of Group Purchasing Organizations 54
3.4.4 Lack of Clinical Data 57
3.4.5 Cost Considerations 59
3.4.6 Reimbursement Trends 60
3.5 Regulatory Issues/Recalls 63
3.5.1 Regulatory Issues 63
3.5.2 Product Recalls 64
3.6 Mergers and Acquisitions/ Key Partnerships 64
3.6.1 Medtronic and Covidien 64
3.6.2 Arterial Remodeling Technologies and Terumo Corporation 65
3.6.3 MicroPort Scientific Corporation and Cordis Corporation 65
3.6.4 Alvimedica and CID 66
3.6.5 ITGI Medical and Vascular Solutions 66
3.6.6 Terumo Corporation and Onset Medical Corporation 66
3.6.7 Atrium Medical and Getinge Group 67
3.6.8 C.R. Bard and ClearStream Technologies 67
3.6.9 Biosensors International and Devax, CardioMind, and JW Medical Systems 68
3.6.10 CeloNova Biosciences and Nexeon MedSystems 69
3.6.11 Medtronic and Invatec 69
3.6.12 Micell Technologies and Maxcor Lifescience 70
3.6.13 Boston Scientific Corporation and Guidant Corporation 70
3.6.14 Abbott Vascular and Guidant Corporation 70
3.6.15 Kaneka Corporation and Fujisawa Pharmaceuticals 71
3.7 Economic Impact of Coronary Artery Disease 71
3.7.1 United States 72
3.8 Treatment Costs for Coronary Artery Disease 73
4 Unmet Needs 75
4.1 Need for Better Clinical Outcomes in Specific Lesions 75
4.1.1 Chronic Total Occlusions 75
4.1.2 Small-Vessel Coronary Lesions 76
4.1.3 Heavily-Calcified and Uncrossable/Undilatable Lesions 77
4.1.4 Bifurcation Lesions 77
4.1.5 Saphenous Vein Graft Intervention 78
4.2 Eliminating Mechanisms of Failure With Balloon Angioplasty 79
4.3 Late Myocardial Infarction After Stenting 79
4.4 Eliminating the Permanent Polymer 80
4.5 In-Stent Restenosis 81
4.6 Stent-In-Stent Procedures 83
4.7 Prolonged Dual Antiplatelet Therapy 84
4.8 Lack of Homogenous Drug Distribution 85
4.9 Delayed Stent Endothelialization 85
4.10 Negative Vessel Remodeling 86
4.11 Need for Effective Therapy for Specific Patient Populations 86
4.12 Addressing the Complications of Coronary Artery Bypass Grafting 87
5 Market Opportunity Analysis 88
5.1 Improve Stent Design/Platform 88
5.1.1 Stent Coating Technology 89
5.1.2 Bioabsorbable Stent Technology 91
5.1.3 Antiproliferative Drug and Elution Kinetics 92
5.2 Hybrid Stent Systems 94
5.3 Effective Therapies for Challenging Coronary Indications 95
5.3.1 Chronic Total Occlusions 95
5.3.2 Small-Vessel Disease 95
5.3.3 Bifurcation Lesions 96
5.3.4 Diffuse Atherosclerotic Disease 97
5.3.5 Saphenous Vein Graft Intervention 97
5.3.6 Acute Myocardial Infarction 97
5.4 Target Challenging Patient Populations 98
5.5 Emerging Markets 99
6 Market Drivers, Barriers, and Substitutes 100
6.1 Market Drivers 100
6.1.1 Rising Prevalence of Disease 101
6.1.2 Viable Treatment for Challenging Coronary Indications 102
6.1.3 Innovations in Stent Technology 103
6.1.4 Development of Bioabsorbable Stents 105
6.1.5 Reduce the Need for Prolonged Dual Antiplatelet Therapy 107
6.1.6 Potential Cost Savings 108
6.1.7 Use of Imaging Modalities for Accurate Stent Placement 109
6.1.8 Adoption of Stents in the Emerging Markets 109
6.1.9 Launch of Bioabsorbable Stents in US and Japan 110
6.2 Market Barriers 110
6.2.1 Concerns Regarding Overstenting 110
6.2.2 Post-ProceduraI Complications of Drug-Eluting Stenting 111
6.2.3 Risk of Perioperative Adverse Cardiac Events Post-Stenting 111
6.2.4 Slow Adoption of Bioabsorbable Stents 112
6.2.5 Lack of Reimbursement 117
6.2.6 Healthcare Cost-Cutting and Reimbursement 118
6.2.7 Availability of Venture Capital 119
6.2.8 Medical Device Excise Tax 120
6.3 Market Substitutes 121
6.3.1 Drug-Eluting Balloons 121
6.3.2 Liquid Drug Delivery Catheter 122
7 Competitive Assessment 124
7.1 Overview 124
7.2 Trends in Coronary Stent Technology Development 125
7.2.1 Development of Bare Metal Stents 125
7.2.2 Development of Drug-Eluting Stents 127
7.2.3 Development of Bioabsorbable Stents 130
7.2.4 Development of Covered Stents 131
7.2.5 Coronary Stent Technology SWOT Analysis 132
7.3 Global Company Market Share 133
7.3.1 Bare Metal Stent Market Share 133
7.3.2 Drug-Eluting Stent Market Share 134
7.4 Regional Company Market Share 135
7.4.1 US Market Share 135
8 Pipeline Products 138
8.1 Overview 138
8.2 Pipeline by Stage of Development 138
8.3 Pipeline Product Profiles 141
8.3.1 Bioabsorbable Stents 141
8.3.2 Other Types of Vascular Stents 152
9 Clinical Trial Analysis 158
9.1 Overview 158
9.2 Clinical Trials to Watch 158
9.2.1 Evaluating the Latest and New Generation of Drug-Eluting Stents 158
9.2.2 Bioabsorbable Stent Clinical Trials 160
9.2.3 Evaluating Stenting in Challenging Coronary Indications/Patient Populations 163
9.2.4 Targeting Patient Populations in the APAC Region 165
10 Current and Future Players 167
10.1 Overview 167
10.2 Trends in Corporate Strategy 167
10.3 Company Profiles 170
10.3.1 Abbott Vascular 170
10.3.2 Boston Scientific Corporation 176
10.3.3 Medtronic 183
10.3.4 Alvimedica 189
10.3.5 Amaranth Medical 193
10.3.6 amg International 196
10.3.7 Arterial Remodeling Technologies 200
10.3.8 B. Braun 203
10.3.9 Balton 206
10.3.10 Biosensors International 211
10.3.11 Biotronik 215
10.3.12 Blue Medical 220
10.3.13 Cardionovum 224
10.3.14 C.R. Bard 228
10.3.15 Elixir Medical Corporation 232
10.3.16 eucatech AG 237
10.3.17 Hexacath 241
10.3.18 IRAMED 244
10.3.19 JW Medical Systems 247
10.3.20 Kyoto Medical Planning 250
10.3.21 Lepu Medical Technology 253
10.3.22 MicroPort Scientific Corporation 257
10.3.23 Minvasys 261
10.3.24 MIV Therapeutics 265
10.3.25 Opto Circuits 269
10.3.26 OrbusNeich Medical 273
10.3.27 Relisys Medical Devices 277
10.3.28 REVA Medical 281
10.3.29 Sahajanand Medical Technologies 284
10.3.30 STENTYS 288
10.3.31 Terumo Corporation 292
10.3.32 Translumina 295
10.3.33 Vascular Concepts 299
10.3.34 Other Companies 303
11 Market Outlook 315
11.1 By Market Segment 315
11.1.1 Overview 315
11.1.2 Drug-Eluting Stent Market 316
11.1.3 Bare Metal Stent Market 317
11.1.4 Emerging Stent Technologies 319
11.2 By Indication 321
11.3 By Geography 322
11.3.1 United States 322
12 Appendix 326
12.1 Bibliography 326
12.2 Abbreviations 350
12.3 Report Methodology 357
12.3.1 Overview 357
12.3.2 Coverage 357
12.3.3 Secondary Research 357
12.4 Physicians and Specialists Included in This Study 359
12.4.1 Praveen Chandra, MD, DM, FESC, FSCAI, FAPSCI 359
12.4.2 Bernado Cortese, MD, FESC 359
12.4.3 Ricardo A. Costa, MD 359
12.4.4 Thomas Cuisset, MD, PhD, FESC 359
12.4.5 Nobuyuki Komiyama, MD, PhD, FACC, FJCC 359
12.4.6 Roger J. Laham, MD 359
12.4.7 Mark W. Mewissen, MD 359
12.4.8 Gary S. Mintz, MD 359
12.4.9 Tudor C. Poerner, MD 360
12.4.10 David Ramsdale, MD, PhD 360
12.4.11 Gregory A. Sgueglia, MD, PhD 360
12.4.12 Madhukar Shahi, MD 360
12.4.13 Takehiro Yamashita, MD, PhD, FACC 360
12.5 Primary Research 361
12.5.1 Primary Research - Key Opinion Leader Interviews 361
12.5.2 Primary Research Interviews- Physician and Industry Participants 361
12.5.3 Physican Survey 362
12.5.4 Expert Panel Validation 363
12.6 Forecasting Methodology 364
12.7 About the Authors 366
12.7.1 Analysts 366
12.7.2 Global Head of Healthcare 367
12.8 About MediPoint 368
12.9 About GlobalData 368
12.10 Disclaimer 368

1.1 List of Tables

Table 1: ACCF/AHA Treatment Guidelines to Improve the Symptoms of CAD* 32
Table 2: Types of CABG 35
Table 3: Complications of CABG 36
Table 4: Drugs Incorporated Into DES 39
Table 5: Types of Lesions Treated Using Atherectomy 43
Table 6: GPOs in the US and EU 55
Table 7: Medicare National Average of Inpatient Hospital Payment for CAD Therapeutic Procedures, 2013-2015 62
Table 8: Direct and Indirect Healthcare Costs of CAD 72
Table 9: Healthcare Expenditures ($bn, 2008$) for CAD in the US, 2011-2020 73
Table 10: US Mean Hospital Costs* ($US) for Cardiac Revascularization Procedures, 2011-2020 74
Table 11: Coronary Stent Technology SWOT Analysis, 2014 132
Table 12: Global Coronary Stent Pipeline Products, 2014 140
Table 13: ART18Z SWOT Analysis, 2014 142
Table 14: DREAMS SWOT Analysis, 2014 143
Table 15: Fantom SWOT Analysis, 2014 144
Table 16: Fortitude SWOT Analysis, 2014 145
Table 17: Ideal BioStent SWOT Analysis, 2014 146
Table 18: Igaki-Tamai Stent SWOT Analysis, 2014 148
Table 19: ON-AVS SWOT Analysis, 2014 149
Table 20: Other Companies Developing BAS, 2014 152
Table 21: FOCUS np Eluting Stent SWOT Analysis, 2014 153
Table 22: STENTYS Sirolimus-Eluting Stent SWOT Analysis, 2014 154
Table 23: Svelte Drug-Eluting Stent SWOT Analysis, 2014 156
Table 24: Clinical Trials Evaluating the Latest and New Generation of DES, 2014 159
Table 25: Clinical Trials Evaluating Stenting in Challenging CAD Indications/Patient Populations, 2014 164
Table 26: Clinical Trials Evaluating Coronary Stenting in APAC Patient Populations, 2014 166
Table 27: Abbott Vascular Company Profile 170
Table 28: Abbott Vascular Coronary Stent Marketed Products 172
Table 29: Abbott Vascular Coronary Stent Product Portfolio SWOT Analysis, 2014 175
Table 30: Abbott Vascular SWOT Analysis, 2014 176
Table 31: Boston Scientific Corporation Company Profile 177
Table 32: Boston Scientific Coronary Stent Marketed Products 179
Table 33: Boston Scientific Coronary Stent Product Portfolio SWOT Analysis, 2014 182
Table 34: Boston Scientific Corporation SWOT Analysis, 2014 183
Table 35: Medtronic Company Profile 184
Table 36: Medtronic Coronary Stent Marketed Products 186
Table 37: Medtronic Coronary Stent Product Portfolio SWOT Analysis, 2014 188
Table 38: Medtronic SWOT Analysis, 2014 189
Table 39: Alvimedica Company Profile 190
Table 40: Alvimedica Coronary Stent Marketed Products 191
Table 41: Alvimedica Coronary Stent Product Portfolio SWOT Analysis, 2014 192
Table 42: Alvimedica SWOT Analysis, 2014 193
Table 43: Amaranth Medical Company Profile 194
Table 44: Amaranth Medical Coronary Stent Pipeline Product 194
Table 45: Amaranth Medical Coronary Stent Product Portfolio SWOT Analysis, 2014 195
Table 46: Amaranth Medical SWOT Analysis, 2014 195
Table 47: amg International Company Profile 196
Table 48: amg International Coronary Stent Marketed Products 198
Table 49: amg International Coronary Stent Product Portfolio SWOT Analysis, 2014 199
Table 50: amg International SWOT Analysis, 2014 200
Table 51: Arterial Remodeling Technologies Company Profile 201
Table 52: Arterial Remodeling Technologies Coronary Stent Pipeline Product 201
Table 53: Arterial Remodeling Technologies Coronary Stent Product Portfolio SWOT Analysis, 2014 202
Table 54: Arterial Remodeling Technologies SWOT Analysis, 2014 202
Table 55: B. Braun Company Profile 203
Table 56: B. Braun Coronary Stent Marketed Products 204
Table 57: B. Braun Coronary Stent Product Portfolio SWOT Analysis, 2014 205
Table 58: B. Braun SWOT Analysis, 2014 206
Table 59: Balton Company Profile 207
Table 60: Balton Coronary Stent Marketed Products 208
Table 61: BALTON Coronary Stent Product Portfolio SWOT Analysis, 2014 210
Table 62: Balton SWOT Analysis, 2014 210
Table 63: Biosensors International Company Profile 211
Table 64: Biosensors International Coronary Stent Marketed Products 213
Table 65: Biosensors International Coronary Stent Product Portfolio SWOT Analysis, 2014 214
Table 66: Biosensors International SWOT Analysis, 2014 215
Table 67: Biotronik Company Profile 216
Table 68: Biotronik Coronary Stent Marketed and Pipeline Products 217
Table 69: Biotronik Coronary Stent Product Portfolio SWOT Analysis, 2014 219
Table 70: Biotronik SWOT Analysis, 2014 220
Table 71: Blue Medical Company Profile 221
Table 72: Blue Medical Coronary Stent Marketed Products 222
Table 73: Blue Medical Coronary Stent Product Portfolio SWOT Analysis, 2014 223
Table 74: Blue Medical SWOT Analysis, 2014 224
Table 75: Cardionovum Company Profile 225
Table 76: Cardionovum Coronary Stent Marketed and Pipeline Products 226
Table 77: Cardionovum Coronary Stent Product Portfolio SWOT Analysis, 2014 227
Table 78: Cardionovum SWOT Analysis, 2014 228
Table 79: C.R. Bard Company Profile 229
Table 80: ClearStream Technologies Coronary Stent Marketed Products 230
Table 81: C.R. Bard Coronary Stent Product Portfolio SWOT Analysis, 2014 231
Table 82: C.R. Bard SWOT Analysis, 2014 232
Table 83: Elixir Medical Corporation Company Profile 233
Table 84: Elixir Medical Corporation Coronary Stent Marketed Products 234
Table 85: Elixir Medical Corporation Coronary Stent Product Portfolio SWOT Analysis, 2014 236
Table 86: Elixir Medical Corporation SWOT Analysis, 2014 237
Table 87: eucatech Profile 238
Table 88: eucatech Coronary Stent Marketed Products 239
Table 89: eucatech Coronary Stent Product Portfolio SWOT Analysis, 2014 240
Table 90: eucatech SWOT Analysis, 2014 241
Table 91: Hexacath Company Profile 242
Table 92: Hexacath Coronary Stent Marketed Products 243
Table 93: Hexacath Coronary Stent Product Portfolio SWOT Analysis, 2014 243
Table 94: Hexacath SWOT Analysis, 2014 244
Table 95: IRAMED Company Profile 244
Table 96: IRAMED Coronary Stent Marketed Products 245
Table 97: IRAMED Coronary Stent Product Portfolio SWOT Analysis, 2014 246
Table 98: IRAMED SWOT Analysis, 2014 247
Table 99: JW Medical Systems Company Profile 248
Table 100: JW Medical Systems Coronary Stent Marketed Product 248
Table 101: JW Medical Systems' Coronary Stent Product Portfolio SWOT Analysis, 2014 249
Table 102: JW Medical Systems SWOT Analysis, 2014 250
Table 103: Kyoto Medical Planning Company Profile 251
Table 104: Kyoto Medical Planning Coronary Stent Pipeline Product 251
Table 105: Kyoto Medical Planning Coronary Stent Product Portfolio SWOT Analysis, 2014 252
Table 106: Kyoto Medical Planning SWOT Analysis, 2014 253
Table 107: Lepu Medical Technology Company Profile 254
Table 108: Lepu Medical Technology Coronary Stent Marketed and Pipeline Products 255
Table 109: Lepu Medical Technology Coronary Stent Product Portfolio SWOT Analysis, 2014 256
Table 110: Lepu Medical Technology SWOT Analysis, 2014 257
Table 111: MicroPort Scientific Corporation Company Profile 258
Table 112: MicroPort Scientific Corporation Coronary Stent Marketed Products 259
Table 113: MicroPort Scientific Corporation Coronary Stent Product Portfolio SWOT Analysis, 2014 260
Table 114: MicroPort Scientific Corporation SWOT Analysis, 2014 261
Table 115: Minvasys Company Profile 262
Table 116: Minvasys Coronary Stent Marketed and Pipeline Products 263
Table 117: Minvasys Coronary Stent Product Portfolio SWOT Analysis, 2014 264
Table 118: Minvasys SWOT Analysis, 2014 265
Table 119: MIV Therapeutics Company Profile 266
Table 120: MIV Therapeutics Coronary Stent Marketed Products 267
Table 121: MIV Therapeutics Coronary Stent Product Portfolio SWOT Analysis, 2014 268
Table 122: MIV Therapeutics SWOT Analysis, 2014 269
Table 123: Opto Circuits Company Profile 270
Table 124: Opto Circuits Coronary Stent Marketed Products 271
Table 125: Opto Circuits Coronary Stent Product Portfolio SWOT Analysis, 2014 272
Table 126: Opto Circuits SWOT Analysis, 2014 273
Table 127: OrbusNeich Medical Company Profile 274
Table 128: OrbusNeich Medical Coronary Stent Marketed and Pipeline Products 275
Table 129: OrbusNeich Medical Coronary Stent Product Portfolio SWOT Analysis, 2014 276
Table 130: OrbusNeich Medical SWOT Analysis, 2014 277
Table 131: Relisys Medical Devices Company Profile 278
Table 132: Relisys Medical Devices Coronary Stent Marketed Products 279
Table 133: Relisys Medical Devices Coronary Stent Product Portfolio SWOT Analysis, 2014 280
Table 134: Relisys Medical Devices SWOT Analysis, 2014 281
Table 135: REVA Medical Company Profile 282
Table 136: REVA Medical Coronary Stent Pipeline Product 282
Table 137: REVA Medical Coronary Stent Product Portfolio SWOT Analysis, 2014 283
Table 138: REVA Medical SWOT Analysis, 2014 284
Table 139: Sahajanand Medical Technologies Company Profile 285
Table 140: Sahajanand Medical Technologies Coronary Stent Marketed and Pipeline Products 286
Table 141: Sahajanand Medical Technologies Coronary Stent Product Portfolio SWOT Analysis, 2014 287
Table 142: Sahajanand Medical Technologies SWOT Analysis, 2014 288
Table 143: STENTYS Company Profile 289
Table 144: STENTYS Coronary Stent Marketed and Pipeline Products 290
Table 145: STENTYS Coronary Stent Product Portfolio SWOT Analysis, 2014 291
Table 146: STENTYS SWOT Analysis, 2014 291
Table 147: Terumo Corporation Company Profile 292
Table 148: Terumo Corporation Coronary Stent Marketed and Pipeline Products 293
Table 149: Terumo Corporation Coronary Stent Product Portfolio SWOT Analysis, 2014 294
Table 150: Terumo Corporation SWOT Analysis, 2014 295
Table 151: Translumina Company Profile 296
Table 152: Translumina Coronary Stent Marketed Products 297
Table 153: Translumina Coronary Stent Product Portfolio SWOT Analysis, 2014 298
Table 154: Translumina SWOT Analysis, 2014 298
Table 155: Vascular Concepts Company Profile 299
Table 156: Vascular Concepts Coronary Stent Marketed Products 300
Table 157: Vascular Concepts Coronary Stent Product Portfolio SWOT Analysis, 2014 301
Table 158: Vascular Concepts SWOT Analysis, 2014 302
Table 159: Other Companies in the Coronary Stent Market, North America, 2014 303
Table 160: Other Companies in the Coronary Stent Market, EU, 2014 308
Table 161: Other Companies in the Coronary Stent Market, APAC, 2014 311
Table 162: Other Companies in the Coronary Stent Market, South Africa and South America, 2014 314
Table 163: Global Coronary Stent Sales ($m) Forecast, by Segment, 2011-2020 315
Table 164: Global DES Sales ($m) Forecast, 2011-2020 316
Table 165: Global BMS Sales ($m) Forecast, 2011-2020 318
Table 166: Coronary Stents Market Sales ($m) Forecast for the United States, 2011-2020 322
Table 167: Primary Research Interviews Completed 362
Table 168: Physicians Surveyed, By Country 363

1.2 List of Figures

Figure 1: Pathophysiology of CAD 30
Figure 2: CAD Treatment Modalities 33
Figure 3: Percentage of Patients with CAD Who Receive Each Therapy Option Only, Global, 2012 and 2019 (N=58) 34
Figure 4: Percentage of Patients with CAD Who Receive Each Type of PCI Only, Global, 2012 and 2019 (N=58) 37
Figure 5: Types of Stents Used to Treat CAD 38
Figure 6: Example of a BMS 39
Figure 7: Example of a DEB 42
Figure 8: Types of Atherectomy 44
Figure 9: US Coronary Stenting Procedure Volume, 2011-2020 48
Figure 10: Healthcare Expenditures ($bn, 2008$) for CAD in the US, 2011-2020 73
Figure 11: US Mean Hospital Costs* ($US) for Cardiac Revascularization Procedures, 2011-2020 74
Figure 12: Percentage of CAD Patients with ISR, Global, 2012 and 2018 (N=58) 82
Figure 13: Percentage of CAD Patients Who Receive Stent-In-Stent Procedures, Global, 2012 and 2018 (N=58) 84
Figure 14: Interventional Cardiologists' Ranking of the Importance of Each Therapy Attribute in Adopting Stents for the Treatment of CAD, Global, 2013 (N=101) 89
Figure 15: Global Coronary Stents Market Value Share (%), 2013 and 2020 125
Figure 16: Global BMS Company Market Share (%), 2013 134
Figure 17: Global DES Company Market Share (%), 2013 135
Figure 18: US Market Share for BMS (%), 2013 136
Figure 19: US Market Share for DES (%), 2013 137
Figure 20: Global Coronary Stent Pipeline Products by Stage of Development, 2014 139
Figure 21: Global Coronary Stents Market Revenue ($m), 2011-2020 316
Figure 22: Global DES Market Revenue ($m), 2011-2020 317
Figure 23: Global BMS Market Revenue ($m), 2011-2020 318
Figure 24: Percentage of Patients (%) Treated with Each Type of Coronary Stent Only, Global, 2013 and 2020 (N=101) 320
Figure 25: Percentage of Patients (%) Treated with Coronary Stents for Each Indication, Global, 2013 and 2020 (N=101) 321
Figure 26: US Sales ($m) Forecast for Coronary Stents, 2011-2020 323

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
European Market Report for Central Venous Catheters 2017 - MedCore

European Market Report for Central Venous Catheters 2017 - MedCore

  • $ 6495
  • Industry report
  • November 2016
  • by iData Research, Inc.

Description The European CVC market includes acute and chronic CVCs. Acute CVCs are classified as either conventional acute CVCs or antimicrobial acute CVCs. The acute CVC market includes conventional ...

European Market Report for Dialysis Catheters 2017 - MedCore

European Market Report for Dialysis Catheters 2017 - MedCore

  • $ 6495
  • Industry report
  • November 2016
  • by iData Research, Inc.

Description The European market for dialysis catheters comprises the acute hemodialysis, chronic hemodialysis and peritoneal dialysis catheter segments. The chronic hemodialysis catheter market is segmented ...

Biodegradable Stents Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024

Biodegradable Stents Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • January 2017
  • by Transparency Market Research

Global Biodegradable Stents Market: Overview Biodegradable Stents are the third generation of stents used in the treatment of coronary artery diseases, which are completely absorbed in the body after the ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.